Sarepta Therapeutics announced that Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, has granted approval for its clinical‑trial application (CTA) for SRP‑1005, the company’s investigational siRNA therapy for Huntington’s disease. The approval allows Sarepta to begin a first‑in‑human, Phase 1, multi‑center, dose‑escalation study—named INSIGHTT—during the second quarter of 2026, with an expected enrollment of 24 participants.
The clearance marks a strategic milestone for Sarepta, which has historically focused on Duchenne muscular dystrophy (DMD) products such as EXONDYS 51 and VYONDYS 53. By advancing SRP‑1005, the company is expanding its portfolio into neurodegenerative disease, a rare‑disease market that could generate new revenue streams once the therapy progresses to later‑stage trials and potential approval. The approval also serves as external validation of Sarepta’s siRNA platform, particularly its transferrin‑receptor‑1 (TfR1) delivery system that targets the central nervous system via subcutaneous administration.
SRP‑1005 is a small interfering RNA that uses a monovalent fragment antigen binding (fAb) to bind TfR1 and deliver the RNA payload into deep brain regions. Preclinical studies have shown significant knockdown of mutant huntingtin protein in key brain areas, supporting the therapeutic rationale. The INSIGHTT study will evaluate safety, tolerability, and pharmacodynamics in a carefully selected cohort of Huntington’s disease patients, providing the first human data for this approach.
Huntington’s disease affects roughly 40,000 symptomatic individuals in the United States and an estimated 200,000 people carry the pathogenic mutation worldwide. The disease is progressive, with no approved disease‑modifying treatments, creating a substantial unmet medical need. SRP‑1005’s potential to reduce mutant protein levels could address this gap and position Sarepta as a pioneer in gene‑silencing therapies for neurodegeneration.
Sarepta’s recent financial performance underscores the importance of pipeline diversification. The company reported preliminary net product revenues of $369.6 million for Q4 2025 and $1.86 billion for the full year, both below analyst expectations. Cash, cash equivalents, and restricted cash totaled $953.8 million as of December 31 2025. The company’s next earnings release is scheduled for February 25 2026, with analysts maintaining a “Hold” consensus rating and a median price target of $19.00.
Louise Rodino‑Klapac, Ph.D., President of Research & Development and Technical Operations, said, “Huntington’s disease is a devastating, progressive condition with extremely limited therapeutic options. SRP‑1005 represents a novel, potentially paradigm‑shifting approach to reduce the mutant protein that drives the disease, and this Medsafe approval is a critical step toward that goal.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.